Copy Link Print Information

Ruxolitinib phosphate

(Synonyms: INCB018424 phosphate)
281 Cited Publications
Kundenbewertung

Based on 281 publication(s) in Google Scholar

Ruxolitinib phosphate (INCB018424 phosphate) is a potent JAK1/2 inhibitor with IC50s of 3.3 nM/2.8 nM, respectively, showing more than 130-fold selectivity over JAK3.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

  • Reinheit : 99.92%
  • CAS. Nr.: 1092939-17-7
  • Formel: C17H21N6O4P
  • Molecular Weight:404.36
  • Speicherung:

    4°C, sealed storage, away from moisture

    * In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

  • Ruxolitinib phosphate Chemical Structure
    Ruxolitinib phosphate Chemical Structure
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
  • Experimental Validation Results for Ruxolitinib phosphate
CAS. Nr.: 1092939-17-7
Größe
Preis
Verfügbarkeit
Menge
Amount: USD 0.00
Please select quantity
or
or

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

To place orders, for customer services and technical support, please contact: MedChemExpress USA

Tel: 609-228-6898 E-mail: [email protected] [email protected]

Data Download
Other Forms of Ruxolitinib phosphate:

To place orders, for customer services and technical support, please contact:

609-228-6898
[email protected] [email protected]
Finden Sie Ihren Händler vor Ort Your local distributor: Hycultec GmbHHycultec
  • Biologische Aktivität
  • Chemical Information
  • Lösungsmittel & Löslichkeit
  • Reinheit & Dokumentation
  • Verweise
  • Help & FAQs
Top Publications Citing

Use of MCE Products

Publications Citing Use of MedChemExpress (MCE) Ruxolitinib phosphate

More
Customer Validation & Images
In Vivo Efficacy Study2D/3D Cell Culture and DifferentiationCell Proliferation/Viability AssayCell Migration/Invasion AssayCell Imaging/StainingRT-PCRFlow CytometryMicrobiological AssayWBIFHistological Imaging/Staining
  • RT-PCR
  • Cell Migration/Invasion Assay
  • Flow Cytometry
  • IF
  • In Vivo Efficacy Study
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • In Vivo Efficacy Study
  • Histological Imaging/Staining
  • RT-PCR
  • 2D/3D Cell Culture and Differentiation
  • Flow Cytometry
  • Microbiological Assay
  • Microbiological Assay
  • Cell Proliferation/Viability Assay
  • WB
  • Cell Imaging/Staining
  • Cell Proliferation/Viability Assay
  • Flow Cytometry
  • 2D/3D Cell Culture and Differentiation
  • WB
  • In Vivo Efficacy Study
  • WB
  • Histological Imaging/Staining
  • IF
  • WB
  • In Vivo Efficacy Study
  • In Vivo Efficacy Study
  • WB
  • RT-PCR
  • Cell Proliferation/Viability Assay
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • RT-PCR
  • IF
  • Cell Proliferation/Viability Assay
  • WB
  • RT-PCR
  • RT-PCR
  • WB
  • WB
  • WB
  • WB
  • WB
  • Cell Proliferation/Viability Assay

Alle JAK Isoform-spezifische Produkte anzeigen

More

Keywords

MOQ
Minimum order quantity
100 mg

Angebot einholen Auf Lager

Other size
Angebot einholen
Please select quantity
Amount: USD 0.00
Sign in to MedChemExpress Einloggen
Registrieren
Sign in to MedChemExpress
Neuen Account Registrieren

At least 6 characters

Personalize your experience, you are currently not signed in. For a better experience, please create an online profile, you can:

Obtain points redemption prizes
Check out faster
Add multiple shipping locations
View orders
Assay Types
  • Ruxolitinib phosphate Chemical Structure
    Ruxolitinib phosphate Chemical Structure
    1/16
  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Science. 2026 Feb 5;391(6785):eadz4075. [Abstract]

    Customer Validation
     Anti-fibrotic effects of FDA-approved oral conpound in cultured mouse ovarian fibroblasts. RT–qPCR analysis of fibrosis markers (Col1a1, Col3a1, Acta2) following a 24-hour treatment with Ruxolitinib (1 μM; 24 h). Ruxolitinib significantly suppressed mRNA expression of fibrosis-associated genes.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

    Customer Validation
     Representative images showing the decreased wound area in the in vitro scratch assay. Ruxolitinib (4 μM; 48 h) pretreatment largely corrected IFN-γ-induced deficits, restoring migration toward control levels.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

    Customer Validation
     Representative flow plots (left) and quantification (right) of apoptosis in hESC-RPE cells treated with vehicle, IFN-γ, Ruxolitinib (4 μM; 48 h) + IFN-γ, or Ruxolitinib (n = 6 technical replicates).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

    Customer Validation
     Left: representative immunofluorescence images of ZO-1 (red) and DAPI (blue) costaining in hESC-RPE cells treated with vehicle, IFN-γ, Ruxolitinib (4 μM; 48 h) + IFN-γ, or Ruxolitinib. Scale bars, 20 μm. Right: quantification of ZO-1 expression (n = 5 technical replicates).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Stem Cell. 2026 Jul 2;33(7):1127-1143.e10. [Abstract]

    Customer Validation
     Representative bioluminescence images tracking luciferase+ hESC-RPE graft survival in NPG mice and hu-mice across groups. Unhumanized NPG mice served as immune-deficient controls.43 Luciferase-expressing hESC-RPE cells were pretreated with Ruxolitinib (4 μM) or vehicle for 48 h, transplanted subcutaneously and monitored by serial bioluminescence imaging. The results showed that in hu-mice receiving vehicle-treated hESC-RPE, bioluminescent signal dropped sharply by day 2, whereas Ruxolitinib-pretreated grafts retained higher signal at days 4, 8, and 12. Signal intensities were initially similar between ruxolitinib-pretreated grafts in hu-mice and vehicle-treated grafts in unhumanized NPG mice, with separation emerging by day 8.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2026 Mar 13. [Abstract]

    Customer Validation
     Competition assay comparing the ratio of SP110-KO versus WT cells on day 7 with the indicated treatments. The results showed that chemical inhibition of interferon signalling using Ruxolitinib (20 µM; 72 h) also prevented cell death in SP110-KO cells.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

    Customer Validation
     Ruxolitinib (JAK/STAT inhibitor, 10 μM; 24 h) prevented Rnf26 upregulation at day 7 in 3D co-culture (qRT‑PCR).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

    Customer Validation
     Ruxolitinib (60 mg/kg; oral gavage; twice daily) suppressed tumor growth in HBC transgenic mice.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2026 Feb 8;86:101375.

    Customer Validation
     Ruxolitinib (60 mg/kg; oral gavage; twice daily) reduced RNF26 expression and enhanced CD3+ T cell infiltration in HBC transgenic mice.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nature. 2025 Jan;637(8046):726-735. [Abstract]

    Customer Validation
     Investigation of the signalling axis regulating LIF expression upon PDGF stimulation. Cells were treated with PDGFR inhibitor crenolanib (0.5 μM), JAK inhibitor Ruxolitinib (1 μM), PI3K inhibitor LY294002 (10 μM), PTPN11 inhibitor SHP099 (10 μM), MEK inhibitor mirdametinib (10 μM), or ERK inhibitor ravoxertinib (10 μM) for 24 h before cell lysis for total RNA extraction and measurement of LIF mRNA levels by real-time qPCR.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 Sep;6(9):1537-1558. [Abstract]

    Customer Validation
     Representative images and immunostaining of DMSO, JSH-23 (1 uM) and Ruxolitinib (10 uM) treated prostate organoids from K5-PTEN mice 5 days following TAM administration and quantification of hyperplastic organoids and YFP+K8+ in total YFP+ cells using indicated antibodies. Scale bar, 500 μm (up), 50 μm (down). n=3 independent experiments. The results showed that treatment of these organoids with JSH-23 and Ruxolitinib decreased the proportion of hyperplastic organoids and basal to luminal transition in vitro.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2025 Sep;6(9):1537-1558. [Abstract]

    Customer Validation
     Representative FACS plot of CD49f and EpCAM expression in YFP+ prostate epithelial cells from DMSO, JSH-23 and Ruxolitinib (10mg/kg; i.p.; 3 times weekly, every other day, for 5 weeks) treated K5-PTEN 6w and K5-PTEN-PIK 3w mice. Ruxolitinib, a JAK1/JAK2 inhibitor, reduced the differentiation of breast carcinoma (BC) into lobular carcinoma (LC) when administered 6 weeks after Pten deletion in BC and 3 weeks following Pten‑Pik3ca targeting in BC.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Dec;27(12):2143-2151. [Abstract]

    Customer Validation
     DTEP formation from A375 WT persister cells treated with 250 nM dabrafenib and 25 nM trametinib for 2 weeks followed by the addition of 1 μM JAK inhibitor Ruxolitinib for 5 weeks. The results showed that the cotreatment of persister cells with JAK inhibitor Ruxolitinib to block IFN signalling increased the proportion of persister cells which regrew into DTEP colonies.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cell Biol. 2025 Dec;27(12):2143-2151. [Abstract]

    Customer Validation
     DTEP formation from PC9 persister cells co-treated with 300 nM osimertinib and 5 μM ruxolitinib for 5 weeks. The results showed that the cotreatment of persister cells with JAK inhibitor Ruxolitinib to block IFN signalling increased the proportion of persister cells which regrew into DTEP colonies.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Adv Funct Mater. 2025 Apr 21.

    Customer Validation
     Cell viability and mRNA transfection efficiency by HEK293T cells concurrently treated with 0, 0.2, 0.5, 1, 2, 5, 10, 20, or 50 μM of Ruxolitinib and Luciferase-mRNA/LNP for 24 h (n = 5–6)

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 8;16(1):6270. [Abstract]

    Customer Validation
     Western blot for the indicated proteins in HEL cells expressing GFP, Empty or NRASQ61K vectors, treated 24 h with Ruxolitinib (3 µM). Ruxolitinib treatment for 24 h resulted in decreased ERK phosphorylation in a RAS WT context.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     Representative images and Caspase 3/7 activity (green) and PI (red) staining of organoids isolated from the ileum of Villin-CreERT2 Adarfl/fl mice and treated without or with 4-OHT (200 nM) and co-treated with 1 μM Ruxolitinib (Rux), Tofacitinib (Tof), Fedratinib (Fed), or Itacitinib (Ita) for 5 days. Scale bars: 100 μm. The results showed that the JAK1/2 dual inhibitor Ruxolitinib showed the best efficacy in rescuing Adar deficiency-induced organoid death, whereas the JAK1 inhibitor Itacitinib, JAK2 inhibitor Fedratinib, and JAK3/2 inhibitor Tofacitinib were not effective.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 29;16(1):6972. [Abstract]

    Customer Validation
     Cell survival of SUM149 BRCA1-Mut and BRCA1-Rev cells transfected with a concentration range (nM) of ADAR1 siRNA in the context of exposure to the JAK/STAT pathway inhibitors (JSPi) Ruxolitinib (10 µM; 5 days).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jul 8;16(1):6270. [Abstract]

    Customer Validation
     Percentage of GFP+ and GFP−_Empty or GFP−_NRASQ61K HEL or UKE-1 cells. 24 days after Ruxolitinib (3 µM and 15 µM for HEL and UKE-1, respectively), the indicated cells were treated 3 days with Ruxolitinib or Ruxolitinib (Ruxo.) and trametinib (Trame.) (10 µM and 0.1 µM for HEL and UKE-1, respectively) (n = 3 biological replicates). The results showed that trametinib treatment partially reverted the Ruxolitinib-induced NRASQ61K cellular fitness increase, suggesting that the MAPK pathway inhibition re-sensitizes NRASQ61K cells to Ruxolitinib.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     Representative images of the growth process of organoids isolated from the ileumof Villin-CreERT2 Adarfl/fl mice and treated without or with 4-OHT (200 nM) and co-treated with 1μMRuxolitinib (Rux), Tofacitinib (Tof), Fedratinib (Fed), or Itacitinib (Ita) for 5 days. The results showed that the JAK1/2 dual inhibitor Ruxolitinib showed the best efficacy in rescuing Adar deficiency-induced organoid death, whereas the JAK1 inhibitor Itacitinib, JAK2 inhibitor Fedratinib, and JAK3/2 inhibitor Tofacitinib were not effective.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 20;16(1):10222. [Abstract]

    Customer Validation
     COX2 and pro-IL-1β protein levels in non-stim and LPS-stimulated WT and m.5019A>G BMDMs treated with Ruxolitinib (1 μM; 1 h) or vehicle control Ab (n = 3; LPS 6 h). Representative blot shown.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     Survival curves of Adarfl/fl and TMX induced AdariΔgut mice co-treated with Ruxolitinib (Rux) (60 mg/kg/day), Tof (40 mg/kg/day), Fed (60 mg/kg/day), or Ita (30 mg/kg/day) by daily i.p. injections for 5 days. The results showed Ruxolitinib, but not other JAK inhibitors, showed the best effect in preventing Adar ablation induced animal death.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Nov 20;16(1):10222. [Abstract]

    Customer Validation
     Inducible nitric oxide synthase (iNOS) protein levels in non-stim and LPS-stimulated WT and m.5019A>G BMDMs treated with Ruxolitinib (1 μM; 1 h) or vehicle control Ab (n = 3; LPS 24 h). Representative blot shown.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     H&E staining of intestine and colon sections. Scale bars: 100 μm. Adarfl/fl and TMX induced AdariΔgut mice co-treated with Ruxolitinib (Rux) (60 mg/kg/day), Tof (40 mg/kg/day), Fed (60 mg/kg/day), or Ita (30 mg/kg/day) by daily i.p. injections for 5 days. The results showed that Ruxolitinib, but not other JAK inhibitors, showed the best effect in preventing Adar ablation-induced mucosal epithelial damage.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     Immunofluorescence of E-cadherin (red), Lysozyme (green) and Muc2 (red). Scale bars: 100 μm. The results showed that Ruxolitinib (Rux) (60 mg/kg/day; i.p.; once daily for 5 days) caused a loss of E-cadherin and Muc2 expression in AdariΔgut mice mice.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Sep 29;16(1):8560. [Abstract]

    Customer Validation
     Western blot analysis of ileal samples. The relative values of protein expression are labeled (n = 3). The results showed that Ruxolitinib (Rux) (60 mg/kg/day; i.p.; once daily for 5 days) caused a loss of E-cadherin and Muc2 expression and increased expression of cleaved caspase 3 and p-Stat1 in AdariΔgut mice.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: N Engl J Med. 2024 May 30;390(20):1873-1884. [Abstract]

    Customer Validation
     Survival rate analysis among groups of the Pilocarpine (Ruxolitinib phosphate) (300 mg/kg; i.p.)-induced SE model.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Jan 18;83(2):264-284. [Abstract]

    Customer Validation
     Graphs depicting SUM149 (top) and SUM190 (bottom) xenograft tumor volume in mice treated with vehicle, paclitaxel (PTX), Ruxolitinib (RUX) (60 mg/kg/day and delivered by subcutaneous osmotic pumps), or the combination, with green arrow depicting treatment start when tumors were first palpable (∼20 mm3 for SUM149 and ∼60 mm3 for SUM190).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cancer Res. 2023 Jan 18;83(2):264-284. [Abstract]

    Customer Validation
     Immunoblot analysis of pSTAT3 and STAT3 in xenografts. ACTB was used as a loading control. Dot plot depicts quantification of pSTAT3/STAT3 ratios. The results showed that Ruxolitinib (RUX, 60 mg/kg/day and delivered by subcutaneous osmotic pumps) significantly decreased pSTAT3 levels in SUM190 xenografts, and while we saw a similar trend in SUM149, these tumors tended to be heterogeneous for pSTAT3.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nature. 2022 Sep;609(7928):785-792. [Abstract]

    Customer Validation
     Huh7 cells are pretreated with DMSO, 5 μM Filgotinib, 5 μM Ruxolitinib or 5 μM IFNα-IFNAR-IN-1 hydrochloride for 1 h and infected with MERS-CoV at a MOI of 1. MERS-CoV N gene copy number is quantified by RT-qPCR.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Cancer. 2022 Sep;3(9):1071-1087. [Abstract]

    Customer Validation
     Relative cell number of LNCaP/AR cells treated with annotated treatment: 10 µM Enzalutamide (Enz), 5 µM Filgotinib (Filg), 5 µM Ruxolitinib (Ruxo), 1 µM Fludarabine (Flu), 0.2 µM Niclosamide (Nic) and DMSO for 8 days.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     Ruxolitinib (100 mg/kg/day; i.p.; 8 weeks) reduced the expression of proinflammatory cytokine genes in the livers of ARE-Del+/− mice. RNA is isolated from the livers of Ruxolitinib-treated mice.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     Levels of IL-6, TNF, and MCP1 production in macrophages isolated from wild-type mice (females/20 weeks) following in vitro treatment with Ruxolitinib were determined utilizing CBA and flow cytometry.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2022 Oct;19(10):1130-1140. [Abstract]

    Customer Validation
     The expression of phosphorylated (p-) and unphosphorylated STAT1 and STAT6 in macrophages is assessed by western blotting. The results demonstrated that pSTAT1 and STAT1 were inhibited in macrophages treated with Ruxolitinib (1-10 μM), while STAT6 was activated concomitantly.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Theranostics. 2022 Oct 3;12(16):7051-7066. [Abstract]

    Customer Validation
     A549 cells were treated with 2.5 µM BVD and 10 µM Ruxolitinib (Rux) separately or in combination for 2 days. Immunoblotting was conducted to determine pSTAT3-Y705.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 May 25;13(5):496. [Abstract]

    Customer Validation
     The xenografts treated with both Trametinib and Ruxolitinib (20 mg/kg; i.p.; every 3 days) show the expression of pSTAT3 and pERK1/2 in xenograft tumors exposed to the indicated treatment. Densitometry analyses of pSTAT3 and pERK1/2 expression normalized to STAT3 and ERK1/2 expression, respectively.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

    Customer Validation
     The induction of MIS target genes Id2, Id3, Smad6, and Igfbp5 was recapitulated as measured by qPCR following a 48 h incubation of ex vivo cultured ovaries from PND2 rat with 1 μM candidate MISR2 agonists Gandotinib, SP600125m, CYC-116, Ruxolitinib.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2022 Apr 12;119(15):e2122512119. [Abstract]

    Customer Validation
     Representative DDX4 immunofluorescence following 48 h incubation of ovaries from PND2 mice cultured ex vivo with 1 μM candidate MISR2 agonists Gandotinib, SP600125, CYC-116, Ruxolitinib.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: J Hematol Oncol. 2021 Jun 24;14(1):97. [Abstract]

    Customer Validation
     Growth curves for DND-41, RPMI-8402 and LOUCY T-ALL cell lines. Growth medium was supplemented with DMSO, MRK-560 100 nM, ruxolitinib 1 µM or both compounds.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2021 Dec;41(12):1354-1372. [Abstract]

    Customer Validation
     The MAGE‐C3 overexpressing KYSE30 cells are treated with Ruxolitinib (2 μM, for 20 h.) and probed for STAT1 expression pSTAT1Tyr701. The pSTAT1Tyr701 expression levels are almost unchanged when exposure to Ruxolitinib in presence with IFN‐γ.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Aug 13;12(1):4917. [Abstract]

    Customer Validation
     The A3A mRNA level is monitored in MCF10A cells 16 h after treatment with 3p-hpRNA and JAK inhibitors (JAKi #1: 2 μM Pacritinib, JAKi #2: 2 μM Ruxolitinib).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cell Rep. 2020 Sep 15;32(11):108158. [Abstract]

    Customer Validation
     Cxcl10 and Ccl5 mRNA levels are analyzed in TNF-α (100 ng/mL)-stimulated BMDMs for 6 h, which are pretreated with notopterol (10 mM) in the presence or absence of Ruxolitinib (10 μM) or SD1029 (10 μM) for 3 h.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Nat Med. 2018 Aug;24(8):1143-1150. [Abstract]

    Customer Validation
     Immunoblot of pSTAT1, STAT1 and β-actin levels in H69AR cells±200 ng/mL IFNg 10 min pulse followed by 24 h chase in media with DMSO, Ruxolitinib (100 nM) or MRT67307 (1 µM).

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2018 May;8(5):616-631. [Abstract]

    Customer Validation
     Analysis of PIM1 RNA and protein expression in HOXA9 positive patient derived xenograft (PDX) samples ex vivo after 1 μM Ruxolitinib over 6 hours.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Clin Cancer Res. 2018 Apr 15;24(8):1917-1931. [Abstract]

    Customer Validation
     Jak2 is inhibited by lentiviral expression of Jak2 shRNA or control shRNA in CWR22Pc and CWR22Rv1 cells. Alternatively, cells are treated with Jak2 inhibitors AZD1480 (0.8 μM) and Ruxolitinib (0.4 μM) (72 h), followed by Western blot analysis of Jak2 and active Stat5a/b.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: JCI Insight. 2018 Sep 6;3(17):e120750. [Abstract]

    Customer Validation
     A431 cells are then treated in full growth media with vehicle, CSA (50 ng/mL), Ruxolitinib (20 μM), or both Ruxolitinib and CSA for 36 hours.

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2015 Nov 27;290(48):29022-34. [Abstract]

    Customer Validation
     106 autonomous Ba/F3 cells stably transduced with ALL-associated JAK3 mutant V674A or double mutant L857P/Y100A are treated with increasing concentration of Ruxolitinib (0–2 μM). Two hours after treatment, the cells are lysed and subjected to Western blot analysis. Phosphorylation of STAT5, JAK3, and JAK1 is detected using specific anti-pY694 STAT5, anti-pY980/81 JAK3, and anti-pY1034/35 JAK1 antibodies. Membranes are reprobed with anti-STAT5, anti-JAK3, anti-JAK1, and anti-β-actin an

  • 1/16

    Ruxolitinib phosphate purchased from MedChemExpress. Usage Cited in: Blood. 2013 Nov 21;122(22):3628-31. [Abstract]

    Customer Validation
     Ruxolitinib decreased spleen weight. Mice were sacrificed on day 21 or 24 to evaluate spleen size.

  • Ruxolitinib phosphate